Mizuho analyst Salim Syed initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Outperform rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage